GLPwatch
Papers (10376)
Page 84 of 173, ranked by citation count.
- The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
- Nasal absorption enhancement of protein drugs independent to their chemical properties in the presence of hyaluronic acid modified with tetraglycine-L-octaarginine.
- Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.
- Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial.
- A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide.
- Osmoadaptive GLP-1R signalling in hypothalamic neurones inhibits antidiuretic hormone synthesis and release.
- Exendin-4 promotes proliferation of adipose-derived stem cells through ERK and JNK signaling pathways.
- Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH-dependent manner.
- Short-term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice.
- iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L.
- A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptors.
- Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea.
- Bullous Pemphigoid Triggered by Liraglutide.
- A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.
- The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- An accidental liraglutide overdose: case report.
- Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1.
- Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study.
- Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study.
- GLP-1 Agonists in Plastic Surgery: Impact on Aesthetic Outcomes-Two Case Reports.
- The Impact of Glucagon-Like Peptide-1 Receptor Agonist on the Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review.
- Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease.
- Comparative effectiveness of exenatide once-weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta-analysis of observational studies.
- Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis.
- Fast-track rescue weight reduction therapy to achieve rapid technical operability for emergency bariatric surgery in patients with life-threatening inoperable severe obesity - A proof of concept study.
- Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register - an IMI-SOPHIA study.
- Otolaryngologic Side Effects of GLP-1 Receptor Agonists.
- Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?
- Noninvasive longitudinal quantification of β-cell mass with [<sup>111</sup>In]-labeled exendin-4.
- A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes.
- GLP-1 modulated the firing activity of nigral dopaminergic neurons in both normal and parkinsonian mice.
- The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.
- A Novel Bioresorbable Device as a Controlled Release System for Protecting Cells from Oxidative Stress from Alzheimer's Disease.
- Comparative effectiveness of semaglutide <i>versus</i> liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.
- Bioengineered Nanomedicines Targeting the Intestinal Fc Receptor Achieve the Improved Glucoregulatory Effect of Semaglutide in a Type 2 Diabetic Mice Model.
- Semaglutide, suicidal ideation and behaviour: A resting state functional magnetic resonance imaging perspective.
- Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK.
- Risk of Hearing Loss in Patients Treated with Exendin-4 Derivatives: A Network Meta-Analysis of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.
- Beta Cell Imaging-From Pre-Clinical Validation to First in Man Testing.
- Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.
- GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
- Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes.
- Individualised incretin-based treatment for type 2 diabetes.
- Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide.
- Semaglutide: a promising new glucagon-like peptide-1 receptor agonist.
- Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome.
- Factors associated with successful weight loss after liraglutide treatment for obesity.
- Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) Improve Periodontal and Peri-Implant Health in Type 2 Diabetes Mellitus.
- Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add-on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA-PRIME).
- Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer's Disease and Parkinson's Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying Therapies.
- Semaglutide: A Novel Oral Glucagon-Like Peptide Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
- Self-inducible secretion of glucagon-like peptide-1 (GLP-1) that allows MIN6 cells to maintain insulin secretion and insure cell survival.
- Effects of the DPP-4 inhibitor, linagliptin, in diet-induced obese rats: a comparison in naive and exenatide-treated animals.
- Characterization of a site-specific PEGylated analog of exendin-4 and determination of the PEGylation site.
- Protective effects of extendin‑4 on hypoxia/reoxygenation‑induced injury in H9c2 cells.
- Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.
- Liraglutide promotes apoptosis of HepG2 cells by activating JNK signaling pathway.
- National trends in prescription drug expenditures and projections for 2025.
- Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China.
- Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2.